[Familial hemophagocytic lymphohistiocytosis: diagnosis, treatment and pathophysiological mechanisms].
Familial hemophagocytic lymphohistiocytosis (FHL) is an invariably fatal disease typically seen in infancy and early childhood, with a median survival without therapy of two months. It is characterized by prolonged fever, hepatosplenomegaly, cytopenia, and deficient NK-cell activity and T-cell cytotoxic capacity. Severe neurological symptoms as well as coagulation disorders and abnormalities in liver function and lipid status may also develop. Since the mid 1980's there has been a remarkable increase in our understanding of this disease. In a large-scale international collaborative effort mediated through the Histiocyte Society, diagnostic criteria and an international treatment protocol (HLH-94) based on immunochemotherapy and BMT have been developed. A large proportion of affected children can now be cured and, moreover, successful chemotherapy in utero of FHL has been achieved. It has been shown that the symptoms and signs are mediated through a pronounced hypercytokinemia. Previous suggestions that FHL may be caused by a deficiency in apoptosis were recently confirmed when perforin gene defects were described, which may well explain the disastrous lymphohistiocytic accumulation and subsequent T-cell activation.
Henter
J I
JI
Astrid Lindgrens barnsjukhus, Karolinska sjukhuset. jan-inge.henter@kbh.ki.se
Samuelsson
A
A
Ericson
K
K
Nilsson-Ardnor
S
S
Elinder
G
G
Fadeel
B
B
D017209:Apoptosis / Q000235:genetics; D016026:Bone Marrow Transplantation; D001921:Brain / Q000473:pathology; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007223:Infant; D008099:Liver / Q000473:pathology; D011379:Prognosis